Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Pharmacology & Pharmacy, Human gastric emptying, Bioavailability, Gastrointestinal mass transport model, Bioequivalence, Aspiration/motility study, Phenol red, Paromomycin, In vivo dissolution, Oral absorption, Nonabsorbable marker, Gastrointestinal, HUMAN GASTROINTESTINAL-TRACT, POORLY ABSORBABLE DRUG, IN-VIVO DISSOLUTION, ORAL DOSAGE FORMS, ABSORPTION, VITRO, MODEL, BIOAVAILABILITY, INDICATORS, MOTILITY, Administration, Oral, Adult, Fasting, Female, Gastric Emptying, Healthy Volunteers, Humans, Intestinal Absorption, Intestine, Small, Male, Middle Aged, Models, Biological, Phenolsulfonphthalein, Postprandial Period, Solubility, Stomach, Young Adult, 1115 Pharmacology and Pharmaceutical Sciences, 3214 Pharmacology and pharmaceutical sciences

Abstract:

The goal of this study was to create a mass transport model (MTM) model for gastric emptying and upper gastrointestinal (GI) appearance that can capture the in vivo concentration-time profiles of the nonabsorbable drug phenol red in solution in the stomach and upper small intestine by direct luminal measurement while simultaneously recording the contractile activity (motility) via manometry. We advanced from a one-compartmental design of the stomach to a much more appropriate, multi-compartmental 'mixing tank' gastric model that reflects drug distribution along the different regions of the stomach as a consequence of randomly dosing relative to the different contractile phases of the migrating motor complex (MMC). To capture the intraluminal phenol red concentrations in the different segments of the GI tract both in fasted and fed state conditions, it was essential to include a bypass flow compartment ('magenstrasse') to facilitate the transport of the phenol red solution directly to the duodenum (fasted state) or antrum (fed state). The fasted and fed state models were validated with external reference data from an independent aspiration study using another nonabsorbable marker (paromomycin). These results will be essential for the development and optimization of computational programs for GI simulation and absorption prediction, providing a realistic gastric physiologically-based pharmacokinetic (PBPK) model based on direct measurement of gastric concentrations of the drug in the stomach.